(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Mouse
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Leu Thr Cys Tyr His Cys Phe Gln Pro Val Val Ser Ser Cys Asn Met
1 5 10 15

Asn Ser Thr Cys Ser Pro Asp Gln Asp Ser Cys Leu Tyr Ala Val Ala
20 25 30

Gly Met Gln Val Tyr Gln Arg Cys Trp Lys Gln Ser Asp Cys His Gly
35 40 45

Glu Ile Ile Met Asp Gln Leu Glu Glu Thr Lys Leu Lys Phe Arg Cys
50 55 60

Cys Gln Phe Asn Leu Cys Asn Lys Ser Asp
65 70

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 82 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Human
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Leu Tyr Glu Leu Ile Tyr Val Leu Asp Lys Ala Ser Met Lys Arg Lys
1 5 10 15

Gly Val Glu Leu Lys Asp Ile Lys Arg Cys Leu Gly Tyr His Leu Asp
20 25 30

Val Ser Leu Ala Phe Ser Glu Ile Ser Val Gly Ala Glu Phe Asn Lys
35 40 45

Asp Asp Cys Val Lys Arg Gly Glu Gly Arg Ala Val Asn Ile Thr Ser
50 55 60

Glu Asn Leu Ile Asp Asp Val Val Ser Leu Ile Arg Gly Gly Thr Arg
65 70 75 80

Lys Tyr

(2) INFORMATION FOR SEQ ID NO:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 86 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide

U.S. PAT NO. 5,843,884

US005843884A

United States Patent [19]

Sims

[11] Patent Number: 5,843,884

[45] Date of Patent: Dec. 1, 1998

[54] **C9 COMPLEMENT INHIBITOR**

[75] Inventor: **Peter J. Sims**, Mequon, Wis.

[73] Assignee: **Oklahoma Medical Research Foundation**, Oklahoma City, Okla.

[21] Appl. No.: **559,492**

[22] Filed: **Nov. 15, 1995**

[51] **Int. Cl.**[6] **A01N 1/00**; A61K 38/00; A61K 39/395; C07K 16/00

[52] **U.S. Cl.** **514/2**; 530/324; 530/387.1; 530/387.2; 424/131.1; 424/138.1

[58] **Field of Search** 424/138.1, 131.1; 536/23.1; 530/300, 350, 324, 387.1, 387.2; 514/2

[56] **References Cited**

U.S. PATENT DOCUMENTS

3,625,214	12/1971	Higuchi	128/260
4,244,946	1/1981	Rivier et al.	424/177
4,305,872	12/1981	Johnston et al.	260/112.5
4,316,891	2/1982	Guillemin et al.	424/177
4,629,784	12/1986	Stammer	530/328
4,789,734	12/1988	Pierschbacher	530/395
4,792,525	12/1988	Ruoslaghti et al.	435/240
4,906,474	3/1990	Langer et al.	424/428
4,925,673	5/1990	Steiner et al.	424/455

FOREIGN PATENT DOCUMENTS

WO 93/01286 1/1993 WIPO .

OTHER PUBLICATIONS

Agrawal, et al., "Oligodeoxynuleoside Phosphoramidates And As Inhibitors of Human Immunodeficiency Virus, "*Proc. Natl. Acad. Sci. USA*, 85:7079–7083 (1988).

Askew, et al,*J. Am. Chem. Soc.*,111:1082–1090 (1989).

Chang, et al., "Identity of a Peptide Domain of Human C9 That Is Bound by the Cell–surface Complement Inhibitor, CD59",*J. Bio. Chem.*, 269 (42):26424–26430 (1994).

Clackson, et al., *Nature*, 352:624–688 (1991).

Daugherty, et al., *Nucl. Acids Res.*, 19:2471–2476 (1991).

Davies, et al., *J. Exp. Med.*,170:637–654 (1989).

Davies, et al., *Immunol. Res.*,12:258–275 (1993)

Dupuis, et al., *Mol. Immunol.*,30:95–100 (1993)

Gregoriadis, Chapter 14. "Liposomes", *Drug Carriers in Biology and Medicine*, 287–341 (Academic Press, 1979).

Hamilton, et al., "Regulatory Control of the Terminal Complement Proteins at the Surface of Human Endothelial Cells: Neutralization of a C5b–9 Inhibitor by Antibody to CD59" *Blood*,76:2572–2577 (1990).

Hamilton, et al., "Complement Proteins C5b–9 Induce Vesiculation of the Endothelial Plasma Membrane and Expose Catalytic Surface for Assembly of the Prothrombinase Enzyme Complex " *J. Bio. Chem.*, 265:3809–3814 (1990).

Harada, et al., *J. Oral Pathol. Med.*(Denmark), 22(f):145–152 (1993).

Hatanaka, et al.,*Biochim. Biophys. Acta Protein Struct. Mol. Enzymol.* 1209:117–122 (1994).

Hattori, et al., "Stimulated Secretion of Endothelial von Willebrand Factor Is Accompanied by Rapid Redistribution to the Cell Surface of the Intracellular Granule Membrane Protein GMP–140" *J. Bio. Chem.*, 264(14):7768–7771 (1989).

Holguin, et al., *J. Clin. Invest.*, 84:7–17 (1989).

Husler, et al., "Chimeras of Human Complement C9 Reveal the site Recognized by Complement Regulatory Protein CD59", *J. Biol. Chem.*, 270(8):3438–3486 (1995).

Husler, et al., "Role of a Disulfide–bonded Peptide Loop within Human Complement C9 in the species–Selectivity of Complement Inhibitor CD59", *Biochem.*, 35(10):3263–3269 (1996).

Itakura, et al., in *Ann. Rev. Biochem.*, 1984 53:323–356 (1984).

Inai, et al., *Histochemistry* (German), 99(5):335–362 (1993).

Kabat, et al., Sequences of Proteins of Immunlogical Interest, 4th Ed. (U.S. Dept. Health and Human Services, Bethesda, MD, 1987).

Lewis & Dean, *Proc. R. Soc. Lond.*, 236:125–140 and (1989) 141–162.

Lublin & Atkinson,*Current Topics Microbio. Immunol.*, 153:123–145 (1989).

Maher, et al., (1989).

McKinaly & Rossman, *Annu. Rev. Pharmacol. Toxicol.*, 29:111–122 (1989).

Medof, et al., *J. Exp. Med.* 160:1558–1578 (1984).

Merrifield, *J. Am. Chem. Soc.*, 85:2149–2154 (1964).

Mulder, et al., *Hum. Immunol.*, 36(3):186–192 (1993).

Narang, et al., in Methods Enzymol., 65:610–620 (1980).

Ninomiya & Sims, "Contribution of the N–Linked Carbohydrate of Erythrocyte Antigen CD59 to Its Complement–inhibitory Activity ", *J. Biol. Chem.*, 267(12):8404–8410 (1992).

Ninomiya & Sims, "The Human Complement Regulatory Protein CD59 Binds to the α–Chain of C8 and to the Domain of C9", *J. Bio. Chem.* , 267(19):13675–13680 (1992).

(List continued on next page.)

Primary Examiner—Lila Feisee
Assistant Examiner—Susan Ungar
Attorney, Agent, or Firm—Arnall Golden & Gregory, LLP

[57] **ABSTRACT**

Pharmaceutical compositions are designed based on the criticality of a portion of C9 for assembly of the C5b9 complex, which specifically modulate binding of CD59 to C9, either molecules structurally mimicking C9 amino acid residues 359 to 384 which bind to CD59 or molecules binding to C9 amino acid residues 359 to 384. Molecules which inhibit CD59 binding include peptides containing residues 359–384 which compete for binding with the other components of the C5b9 complex and anti-idiotypic antibodies immunoreactive with C9 amino acid residues 359 to 384. Molecules which prevent assembly of the C5b-9 complex include antibodies and antibody fragments immunoreactive with amino acid residues 359 to 384 of C9, peptides that bind to amino acid residues 359 to 384 of C9, and nucleotide molecules that bind to amino acid residues 359 to 384 of C9.

4 Claims, 4 Drawing Sheets

First Hit Fwd Refs Previous Doc Next Doc Go to Doc#
End of Result Set

Generate Collection Print

L2: Entry 1 of 1 File: USPT Dec 1, 1998

US-PAT-NO: 5843884
DOCUMENT-IDENTIFIER: US 5843884 A

TITLE: C9 complement inhibitor

DATE-ISSUED: December 1, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sims; Peter J.	Mequon	WI		

US-CL-CURRENT: 514/2; 424/131.1, 424/138.1, 530/324, 530/387.1, 530/387.2

CLAIMS:

I claim:

1. A composition comprising molecules specifically modulating binding of CD59 to C9 selected from the group of molecules consisting of peptides of between 26 and 30 amino acids which bind to CD59 and molecules binding to C9 amino acid residues 359 to 384 (amino acid residues 381-406 of SEQ. ID NO. 5).

2. The composition of claim 1 comprising molecules selected from the group of molecules consisting of peptides of between 26 and 30 amino acids comprising hu C9 amino acid residues 359 to 384 (amino acid residues 381-406 of SEQ. ID NO. 5), anti-idiotypic antibodies immunoreactive with C9 amino acid residues 359 to 384 (amino acid residues 381-406 of SEQ. ID NO. 5), and covalently cyclized peptides comprising hu C9 amino acid residues 359 to 384 (amino acid residues 381-406 of SEQ. ID NO. 5).

3. The composition of claim 2 wherein the molecules are a peptide including amino acid residues 359 to 384 of hu C9 (amino acid residues 381-406 of SEQ. ID NO. 5).

4. The composition of claim 1 further comprising a pharmaceutically acceptable carrier for administration to patients in need thereof.

Previous Doc Next Doc Go to Doc#